JW Pharmaceutical
JW Pharmaceutical operates in the healthcare sector, focusing on the development and distribution of medical products and quasi drugs. The company is recognized as a leading player in the global pharmaceutical market, with a diverse portfolio that includes original medicines and medical supplies such as Livalo, Thrupas, Sigmart, and Actemra. Additionally, JW Pharmaceutical is committed to improving patient care by creating specialized dietary products, including low-protein and low-salt food options for individuals with chronic renal insufficiency. Through its comprehensive range of pharmaceutical and healthcare products, the company aims to meet the evolving needs of patients and healthcare providers.
3 past transactions
ProGen Company
Post in 2025
ProGen Company is a biopharmaceutical development venture specializing in research and development. The company is dedicated to advancing treatments for metabolic diseases, immune diseases, and cancer through its innovative immunology-based drug development expertise. ProGen utilizes a multi-target fusion protein technology platform to discover new drug candidates, fostering continuous partnerships with leading pharmaceutical companies to enhance its development efforts. By focusing on both domestic and international open innovation, ProGen aims to create valuable drug solutions while pursuing growth through collaborative ventures and technology transfers.
S&E bio
Venture Round in 2022
S&E Bio is a biopharmaceutical company specializing in the development of cell therapies aimed at addressing neurological disorders. The company focuses on creating safe and effective treatments using stem cell-derived extracellular vesicles, particularly mesenchymal stem cell-derived therapeutics. S&E Bio targets a range of conditions, including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. Through its innovative approach to stem cell therapy, the company seeks to provide advanced treatment options for patients suffering from these incurable diseases, enhancing their quality of life and treatment outcomes.
Argonaut Therapeutics
Corporate Round in 2018
Argonaut Therapeutics Limited is a precision therapeutics company based in Oxford, United Kingdom, founded in 2016. The company focuses on developing innovative epigenetically acting drugs aimed at treating cancer by targeting abnormal arginine methylation. Argonaut's therapies are designed to reprogram cancer cells, encouraging them to undergo the body's natural process of cell death. This approach aims to provide advanced treatment options for patients, potentially enhancing recovery times and outcomes. The foundation of Argonaut's research is rooted in pioneering work conducted at the University of Oxford.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.